HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Catherine Mollereau Selected Research

phenylalanyl- leucyl- phenylalanyl- glutaminyl- prolyl- glutaminyl- arginyl- phenylalaninamide

11/2014Nonpeptide small molecule agonist and antagonist original leads for neuropeptide FF1 and FF2 receptors.
4/2012GRK2 protein-mediated transphosphorylation contributes to loss of function of μ-opioid receptors induced by neuropeptide FF (NPFF2) receptors.
1/2011Neuropeptide FF receptor modulates potassium currents in a dorsal root ganglion cell line.
11/2010Opioid-modulating properties of the neuropeptide FF system.
8/2008Neuropeptide FF-sensitive confinement of mu opioid receptor does not involve lipid rafts in SH-SY5Y cells.
5/2007Staurosporine differentiation of NPFF2 receptor-transfected SH-SY5Y neuroblastoma cells induces selectivity of NPFF activity towards opioid receptors.
5/2006Anti-opioid activities of NPFF1 receptors in a SH-SY5Y model.
1/2006RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with hyperalgesia.
3/2005Neuropeptide FF (NPFF) analogs functionally antagonize opioid activities in NPFF2 receptor-transfected SH-SY5Y neuroblastoma cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Catherine Mollereau Research Topics

Disease

7Neuroblastoma
05/2014 - 03/2005
4Hyperalgesia
03/2015 - 01/2006
3Opioid-Related Disorders (Opiate Addiction)
11/2014 - 01/2005
3Pain (Aches)
11/2010 - 01/2005
2Obesity
12/2020 - 12/2019
2Chronic Pain
03/2015 - 01/2006
1Infections
12/2019
1Pathologic Processes
01/2012

Drug/Important Bio-Agent (IBA)

10Opioid Analgesics (Opioids)IBA
12/2020 - 01/2005
9phenylalanyl- leucyl- phenylalanyl- glutaminyl- prolyl- glutaminyl- arginyl- phenylalaninamideIBA
11/2014 - 03/2005
2NeuropeptidesIBA
12/2020 - 11/2014
2neuropeptide FF receptorIBA
03/2015 - 01/2006
2mu Opioid Receptors (mu Opioid Receptor)IBA
11/2014 - 05/2014
2delta Opioid Receptors (delta Opioid Receptor)IBA
05/2006 - 03/2005
1ThrombinFDA Link
12/2019
1PeptidomimeticsIBA
03/2015
1OrnithineIBA
03/2015
1G-Protein-Coupled Receptor KinasesIBA
11/2014
1LigandsIBA
11/2014
13- ((3- cholamidopropyl)dimethylammonium)- 1- propanesulfonate (CHAPS)IBA
05/2014
1Detergents (Detergent)IBA
05/2014
1CalciumIBA
04/2012
1G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA
01/2012
1Opioid Receptors (Opioid Receptor)IBA
05/2007
1StaurosporineIBA
05/2007
1Heroin (Diamorphine)IBA
01/2006

Therapy/Procedure

2Analgesia
12/2020 - 03/2015